Helix Biopharma (OTCMKTS:HBPCF) Announces Earnings Results, Beats Estimates By $0.07 EPS

Helix Biopharma (OTCMKTS:HBPCF) released its earnings results on Friday. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.07, Zacks reports.

Helix Biopharma Price Performance

Shares of Helix Biopharma stock remained flat at $1.71 during midday trading on Friday. Helix Biopharma has a twelve month low of $1.71 and a twelve month high of $1.73. The firm’s 50-day moving average is $1.72 and its two-hundred day moving average is $1.73. The company has a market cap of $130.61 million, a P/E ratio of -34.20 and a beta of 0.17.

About Helix Biopharma

Helix BioPharma Corp is a clinical‐stage biotechnology company focused on the research, development and commercialization of immunotherapeutic drug candidates for oncology and rare disease indications. Headquartered in Laval, Quebec, the company leverages proprietary platforms designed to activate or modulate the immune system, with programs spanning small‐molecule immunoconjugates and biologic modalities. Its lead candidate, L-DOS47, is an antibody‐based immunoconjugate in clinical evaluation for non–small cell lung cancer, and Helix maintains additional discovery‐stage assets targeting solid tumors and hematological malignancies.

Founded in 1983, Helix BioPharma has built a global network of collaborations with academic research centers and contract research organizations across North America and Europe.